2. Search Result
Search Result
Results for "

dyskinesias

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

3

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12723
    Apomorphine
    Maximum Cited Publications
    6 Publications Verification

    (-)-Apomorphine

    		 Dopamine Receptor 5-HT Receptor Neurological Disease
    Apomorphine is an orally active agonist of Dopamine receptor. Apomorphine can be used in study Parkinson, biphasic dyskinesias, urinary dysfunction,,dystonia, dyspnoea, anismus and belching .
    Apomorphine
  • HY-14859
    Dipraglurant

    ADX48621

    		 mGluR Neurological Disease
    Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Dipraglurant
  • HY-15257
    Mavoglurant
    3 Publications Verification

    AFQ056

    		 mGluR Neurological Disease
    Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mavoglurant
  • HY-P1335A
    CTAP TFA
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
    CTAP TFA
  • HY-B1744S
    Pyridoxal phosphate-d5

    		Reverse Transcriptase Endogenous Metabolite Neurological Disease
    Pyridoxal phosphate-d5 is the deuterium labeled Pyridoxal phosphate. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia[1][2].
    Pyridoxal phosphate-d5
  • HY-153472
    VMAT2-IN-2 tosylate

    		Monoamine Transporter Neurological Disease
    VMAT2-IN-2 tosylate is a potent VMAT2 inhibitor. VMAT2-IN-2 tosylate can be used in research of tardive dyskinesia .
    VMAT2-IN-2 tosylate
  • HY-118238
    Remeglurant

    MRZ-8456

    		 mGluR Neurological Disease
    Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC50 of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD) .
    Remeglurant
  • HY-105034A
    Tiospirone hydrochloride

    BMY 13859-1; MJ 13859-1

    		 Others Neurological Disease
    Tiospirone (MJ 13859-1) hydrochloride is an orally active antipsychotic agent that reduces or eliminates tardive dyskinesia (TD) in Cebus apella monkeys with persistent TD .
    Tiospirone hydrochloride
  • HY-P1335
    CTAP

    		Opioid Receptor Neurological Disease
    CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
    CTAP
  • HY-W152604
    Cyclo(glycyl-L-leucyl)

    Cyclo(leu-gly)

    		 Dopamine Receptor Neurological Disease
    Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .
    Cyclo(glycyl-L-leucyl)
  • HY-B1744
    Pyridoxal phosphate
    1 Publications Verification

    Pyridoxal 5′-phosphate; Pyridoxyl phosphate

    		 Reverse Transcriptase Endogenous Metabolite Neurological Disease
    Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.
    Pyridoxal phosphate
  • HY-16771B
    Valbenazine dihydrochloride

    NBI-98854 dihydrochloride

    		 Others Neurological Disease
    Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
    Valbenazine dihydrochloride
  • HY-N11021
    Feruloyl tyramine

    		Others Others
    Feruloyl tyramine, an amide compound, can be isolated from ethanol extract of hemp seed. Feruloyl tyramine injected into the lateral ventricle caused hypothermia and dyskinesia in mice .
    Feruloyl tyramine
  • HY-B1744R
    Pyridoxal phosphate (Standard)

    		Reverse Transcriptase Endogenous Metabolite Neurological Disease
    Pyridoxal phosphate (Standard) is the analytical standard of Pyridoxal phosphate. This product is intended for research and analytical applications. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of reverse transcriptases, and is used for the treatment of tardive dyskinesia.
    Pyridoxal phosphate (Standard)
  • HY-109139A
    Taminadenant mesylate

    NIR178 mesylate; PBF509 mesylate

    		 Adenosine Receptor Cancer
    Taminadenant mesylate (NIR178 mesylate) is a potent adenosine A2A receptor antagonist with potential anti-tumor activity. Taminadenant mesylate can selectively bind and inhibit A2AR on T lymphocytes, thereby releasing adenosine/A2AR-mediated inhibition of T lymphocytes and activating T cell-mediated immune responses against tumor cells. Taminadenant mesylate works by reducing the proliferation of susceptible tumor cells. Taminadenant mesylate also showed effectiveness in reversing dyskinesias in Parkinson's disease models and was able to inhibit dyskinesias caused by L-DOPA .
    Taminadenant mesylate
  • HY-121203A
    Citalopram oxalate

    		Others Neurological Disease
    Citalopram oxalate is a serotonin uptake inhibitor that serves as an antidepressant, effectively reducing ethanol uptake in alcoholics and offering a preferable option for depressed patients experiencing tardive dyskinesia compared to tricyclic antidepressants, which may worsen this condition.
    Citalopram oxalate
  • HY-19199
    E-3620

    		5-HT Receptor Neurological Disease Metabolic Disease
    E-3620 is a potent 5-HT3 receptor antagonist. E-3620 can be used for the research of dyskinesi and gastrointestinal motility .
    E-3620
  • HY-14561A
    Idazoxan hydrochloride

    RX 781094 hydrochloride

    		 Adrenergic Receptor Imidazoline Receptor Neurological Disease Endocrinology
    Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .
    Idazoxan hydrochloride
  • HY-118956
    Adrogolide hydrochloride

    ABT-431 hydrochloride; DAS-431 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .
    Adrogolide hydrochloride
  • HY-100820R
    Sarizotan (Standard)

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Sarizotan (Standard) is the analytical standard of Sarizotan. This product is intended for research and analytical applications. Sarizotan (EMD 128130) is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively .
    Sarizotan (Standard)
  • HY-100820
    Sarizotan
    1 Publications Verification

    EMD 128130

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Sarizotan (EMD 128130) is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively .
    Sarizotan
  • HY-100820B
    Sarizotan dihydrochloride

    EMD 128130 dihydrochloride

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Sarizotan dihydrochloride (EMD 128130) is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively .
    Sarizotan dihydrochloride
  • HY-100820A
    Sarizotan hydrochloride

    EMD 128130 hydrochloride

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Sarizotan hydrochloride is an orally active serotonin 5-HT1A receptor and dopamine receptor agonist. Sarizotan hydrochloride (EMD 128130) exhibits IC50 values of 6.5 nM (rat 5-HT1A), 0.1 nM (human 5-HT1A), 15.1 nM (rat D2), 17 nM (human D2), 6.8 nM (human D3) and 2.4 nM (human D4.2), respectively .
    Sarizotan hydrochloride
  • HY-119093
    Halopemide

    		Phospholipase Dopamine Receptor Neurological Disease Cancer
    Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
    Halopemide
  • HY-131678
    Palmitoyl serotonin

    PA-5HT

    		 Others Neurological Disease
    Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .
    Palmitoyl serotonin
  • HY-W116433
    SK609

    		Others Neurological Disease
    SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .
    SK609
  • HY-118931
    EF-1502

    		Others Neurological Disease
    EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .
    EF-1502
  • HY-120206B
    Brasofensine sulfate

    BMS-204756 sulfate

    		 Monoamine Oxidase Neurological Disease
    Brasofensine (BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .
    Brasofensine sulfate
  • HY-120206
    Brasofensine

    BMS-204756

    		 Monoamine Oxidase Neurological Disease
    Brasofensine (BMS-204756) is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .
    Brasofensine
  • HY-120206A
    Brasofensine maleate

    BMS-204756 maleate

    		 Monoamine Oxidase Neurological Disease
    Brasofensine maleate(BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .
    Brasofensine maleate
  • HY-12707R
    Piribedil (Standard)

    		Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil (Standard)
  • HY-12707
    Piribedil
    1 Publications Verification

    		 Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil
  • HY-12707A
    Piribedil dihydrochloride

    		Adrenergic Receptor Dopamine Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil dihydrochloride
  • HY-12707C
    Piribedil hydrochloride

    		Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil hydrochloride
  • HY-149542
    GSK-3β inhibitor 15

    		Tau Protein Apoptosis GSK-3 Neurological Disease
    GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .
    GSK-3β inhibitor 15
  • HY-12707B
    Piribedil maleate

    		Dopamine Receptor Adrenergic Receptor Histone Methyltransferase Neurological Disease Endocrinology Cancer
    Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers .
    Piribedil maleate
  • HY-B1904
    Fluphenazine decanoate

    		Dopamine Receptor Neurological Disease
    Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
    Fluphenazine decanoate
  • HY-B1904A
    Fluphenazine decanoate dihydrochloride

    		Dopamine Receptor Neurological Disease
    Fluphenazine decanoate dihydrochloride is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
    Fluphenazine decanoate dihydrochloride
  • HY-B1904R
    Fluphenazine decanoate (Standard)

    		Dopamine Receptor Neurological Disease
    Fluphenazine decanoate (Standard) is the analytical standard of Fluphenazine decanoate. This product is intended for research and analytical applications. Fluphenazine decanoate is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research .
    Fluphenazine decanoate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: